Gyre Therapeutics (GYRE) Competitors

$6.48 +0.35 (+5.71%)

Closing price 04:00 PM Eastern

Extended Trading

$6.47 -0.01 (-0.15%)

As of 06:10 PM Eastern

GYRE vs. KOD, NTLA, TRVI, PHVS, and AUPH

Should you buy Gyre Therapeutics stock or one of its competitors? MarketBeat compares Gyre Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Gyre Therapeutics include Kodiak Sciences (KOD), Intellia Therapeutics (NTLA), Trevi Therapeutics (TRVI), Pharvaris (PHVS), and Aurinia Pharmaceuticals (AUPH). These companies are all part of the "pharmaceutical products" industry.

How does Gyre Therapeutics compare to Kodiak Sciences?

Kodiak Sciences (NASDAQ:KOD) and Gyre Therapeutics (NASDAQ:GYRE) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, media sentiment, risk, earnings and profitability.

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 45.9% of Kodiak Sciences shares are owned by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Kodiak Sciences has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat Kodiak Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kodiak Sciences	N/A	-253.85%	-81.48%
Gyre Therapeutics	-5.44%	3.13%	2.67%

Kodiak Sciences presently has a consensus target price of $42.14, suggesting a potential upside of 17.08%. Gyre Therapeutics has a consensus target price of $17.00, suggesting a potential upside of 162.35%. Given Gyre Therapeutics' higher probable upside, analysts clearly believe Gyre Therapeutics is more favorable than Kodiak Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kodiak Sciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Kodiak Sciences has a beta of 2.21, meaning that its stock price is 121% more volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market.

Gyre Therapeutics has higher revenue and earnings than Kodiak Sciences. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Kodiak Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kodiak Sciences	N/A	N/A	-$229.97M	-$4.17	N/A
Gyre Therapeutics	$116.59M	5.39	$5.03M	-$0.09	N/A

In the previous week, Kodiak Sciences had 1 more articles in the media than Gyre Therapeutics. MarketBeat recorded 1 mentions for Kodiak Sciences and 0 mentions for Gyre Therapeutics. Kodiak Sciences' average media sentiment score of 0.00 equaled Gyre Therapeutics'average media sentiment score.

Company	Overall Sentiment
Kodiak Sciences	Neutral
Gyre Therapeutics	Neutral

Summary

Kodiak Sciences beats Gyre Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Gyre Therapeutics compare to Intellia Therapeutics?

Intellia Therapeutics (NASDAQ:NTLA) and Gyre Therapeutics (NASDAQ:GYRE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment, risk and earnings.

Gyre Therapeutics has higher revenue and earnings than Intellia Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intellia Therapeutics	$67.67M	32.00	-$412.69M	-$3.54	N/A
Gyre Therapeutics	$116.59M	5.39	$5.03M	-$0.09	N/A

In the previous week, Intellia Therapeutics had 1 more articles in the media than Gyre Therapeutics. MarketBeat recorded 1 mentions for Intellia Therapeutics and 0 mentions for Gyre Therapeutics. Intellia Therapeutics' average media sentiment score of 0.61 beat Gyre Therapeutics' score of 0.00 indicating that Intellia Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Intellia Therapeutics	Positive
Gyre Therapeutics	Neutral

88.8% of Intellia Therapeutics shares are held by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are held by institutional investors. 3.5% of Intellia Therapeutics shares are held by company insiders. Comparatively, 9.5% of Gyre Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Intellia Therapeutics has a beta of 1.92, suggesting that its share price is 92% more volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

Intellia Therapeutics currently has a consensus price target of $20.46, suggesting a potential upside of 31.98%. Gyre Therapeutics has a consensus price target of $17.00, suggesting a potential upside of 162.35%. Given Gyre Therapeutics' higher probable upside, analysts clearly believe Gyre Therapeutics is more favorable than Intellia Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intellia Therapeutics	3 Sell rating(s)	10 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.35
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Gyre Therapeutics has a net margin of -5.44% compared to Intellia Therapeutics' net margin of -597.04%. Gyre Therapeutics' return on equity of 3.13% beat Intellia Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intellia Therapeutics	-597.04%	-57.47%	-46.24%
Gyre Therapeutics	-5.44%	3.13%	2.67%

Summary

Intellia Therapeutics beats Gyre Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Gyre Therapeutics compare to Trevi Therapeutics?

Trevi Therapeutics (NASDAQ:TRVI) and Gyre Therapeutics (NASDAQ:GYRE) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

Trevi Therapeutics has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat Trevi Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Trevi Therapeutics	N/A	-24.53%	-23.37%
Gyre Therapeutics	-5.44%	3.13%	2.67%

Trevi Therapeutics has a beta of 1.04, indicating that its share price is 4% more volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market.

Trevi Therapeutics presently has a consensus target price of $22.90, indicating a potential upside of 31.42%. Gyre Therapeutics has a consensus target price of $17.00, indicating a potential upside of 162.35%. Given Gyre Therapeutics' higher possible upside, analysts plainly believe Gyre Therapeutics is more favorable than Trevi Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Trevi Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	3.00
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Trevi Therapeutics had 3 more articles in the media than Gyre Therapeutics. MarketBeat recorded 3 mentions for Trevi Therapeutics and 0 mentions for Gyre Therapeutics. Trevi Therapeutics' average media sentiment score of 0.16 beat Gyre Therapeutics' score of 0.00 indicating that Trevi Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Trevi Therapeutics	Neutral
Gyre Therapeutics	Neutral

95.8% of Trevi Therapeutics shares are held by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are held by institutional investors. 18.3% of Trevi Therapeutics shares are held by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Gyre Therapeutics has higher revenue and earnings than Trevi Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Trevi Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trevi Therapeutics	N/A	N/A	-$42.76M	-$0.32	N/A
Gyre Therapeutics	$116.59M	5.39	$5.03M	-$0.09	N/A

Summary

Trevi Therapeutics beats Gyre Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Gyre Therapeutics compare to Pharvaris?

Pharvaris (NASDAQ:PHVS) and Gyre Therapeutics (NASDAQ:GYRE) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Pharvaris has a beta of -2.35, suggesting that its share price is 335% less volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.9, suggesting that its share price is 90% more volatile than the broader market.

24.0% of Gyre Therapeutics shares are held by institutional investors. 11.8% of Pharvaris shares are held by insiders. Comparatively, 9.5% of Gyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Pharvaris had 5 more articles in the media than Gyre Therapeutics. MarketBeat recorded 5 mentions for Pharvaris and 0 mentions for Gyre Therapeutics. Pharvaris' average media sentiment score of 0.16 beat Gyre Therapeutics' score of 0.00 indicating that Pharvaris is being referred to more favorably in the media.

Company	Overall Sentiment
Pharvaris	Neutral
Gyre Therapeutics	Neutral

Pharvaris presently has a consensus target price of $49.18, indicating a potential upside of 47.74%. Gyre Therapeutics has a consensus target price of $17.00, indicating a potential upside of 162.35%. Given Gyre Therapeutics' higher probable upside, analysts clearly believe Gyre Therapeutics is more favorable than Pharvaris.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharvaris	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Pharvaris has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -5.44%. Gyre Therapeutics' return on equity of 3.13% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharvaris	N/A	-67.56%	-61.13%
Gyre Therapeutics	-5.44%	3.13%	2.67%

Gyre Therapeutics has higher revenue and earnings than Pharvaris. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Pharvaris, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharvaris	N/A	N/A	-$198.79M	-$3.18	N/A
Gyre Therapeutics	$116.59M	5.39	$5.03M	-$0.09	N/A

Summary

Gyre Therapeutics beats Pharvaris on 8 of the 15 factors compared between the two stocks.

How does Gyre Therapeutics compare to Aurinia Pharmaceuticals?

Aurinia Pharmaceuticals (NASDAQ:AUPH) and Gyre Therapeutics (NASDAQ:GYRE) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, media sentiment, analyst recommendations, profitability, risk, dividends and earnings.

Aurinia Pharmaceuticals has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market.

Aurinia Pharmaceuticals presently has a consensus price target of $17.25, indicating a potential downside of 7.36%. Gyre Therapeutics has a consensus price target of $17.00, indicating a potential upside of 162.35%. Given Gyre Therapeutics' higher probable upside, analysts clearly believe Gyre Therapeutics is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aurinia Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aurinia Pharmaceuticals has a net margin of 99.97% compared to Gyre Therapeutics' net margin of -5.44%. Aurinia Pharmaceuticals' return on equity of 26.62% beat Gyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aurinia Pharmaceuticals	99.97%	26.62%	19.65%
Gyre Therapeutics	-5.44%	3.13%	2.67%

Aurinia Pharmaceuticals has higher revenue and earnings than Gyre Therapeutics. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aurinia Pharmaceuticals	$283.05M	8.46	$287.20M	$2.17	8.58
Gyre Therapeutics	$116.59M	5.39	$5.03M	-$0.09	N/A

In the previous week, Aurinia Pharmaceuticals had 1 more articles in the media than Gyre Therapeutics. MarketBeat recorded 1 mentions for Aurinia Pharmaceuticals and 0 mentions for Gyre Therapeutics. Aurinia Pharmaceuticals' average media sentiment score of 0.50 beat Gyre Therapeutics' score of 0.00 indicating that Aurinia Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Aurinia Pharmaceuticals	Positive
Gyre Therapeutics	Neutral

36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 12.2% of Aurinia Pharmaceuticals shares are owned by company insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Aurinia Pharmaceuticals beats Gyre Therapeutics on 13 of the 15 factors compared between the two stocks.

Get Gyre Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GYRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GYRE vs. The Competition

Export

Metric	Gyre Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$594.78M	$3.49B	$6.74B	$12.32B
Dividend Yield	N/A	2.28%	2.68%	5.88%
P/E Ratio	-71.99	20.50	25.39	23.96
Price / Sales	5.39	328.65	530.17	107.90
Price / Cash	27.59	130.96	45.29	53.76
Price / Book	4.38	8.26	10.76	6.41
Net Income	$5.03M	$23.91M	$3.56B	$337.14M
7 Day Performance	6.58%	3.05%	1.37%	-0.48%
1 Month Performance	6.93%	2.40%	0.81%	0.49%
1 Year Performance	-14.85%	56.35%	30.53%	28.16%

Gyre Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GYRE Gyre Therapeutics	2.0674 of 5 stars	$6.48 +5.7%	$17.00 +162.3%	-21.1%	$594.78M	$116.59M	N/A	40	Positive News
KOD Kodiak Sciences	1.4504 of 5 stars	$32.94 -3.3%	$42.14 +27.9%	+920.7%	$2.13B	N/A	N/A	90
NTLA Intellia Therapeutics	3.1328 of 5 stars	$14.55 -2.5%	$20.46 +40.6%	+65.2%	$2.08B	$67.67M	N/A	600
TRVI Trevi Therapeutics	2.5703 of 5 stars	$15.40 +5.0%	$22.90 +48.7%	+202.3%	$2.08B	N/A	N/A	20	News Coverage High Trading Volume
PHVS Pharvaris	3.4896 of 5 stars	$31.46 -0.3%	$49.18 +56.3%	+90.5%	$2.06B	N/A	N/A	30

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GYRE) was last updated on 6/24/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Gyre Therapeutics (GYRE) Competitors

GYRE vs. KOD, NTLA, TRVI, PHVS, and AUPH

How does Gyre Therapeutics compare to Kodiak Sciences?

Summary

How does Gyre Therapeutics compare to Intellia Therapeutics?

Summary

How does Gyre Therapeutics compare to Trevi Therapeutics?

Summary

How does Gyre Therapeutics compare to Pharvaris?

Summary

How does Gyre Therapeutics compare to Aurinia Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GYRE vs. The Competition

Gyre Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Gyre Therapeutics (GYRE) Competitors

GYRE vs. KOD, NTLA, TRVI, PHVS, and AUPH

How does Gyre Therapeutics compare to Kodiak Sciences?

Do insiders & institutionals have more ownership in KOD or GYRE?

Is KOD or GYRE more profitable?

Do analysts prefer KOD or GYRE?

Which has more volatility and risk, KOD or GYRE?

Which has preferable valuation & earnings, KOD or GYRE?

Does the media prefer KOD or GYRE?

Summary

How does Gyre Therapeutics compare to Intellia Therapeutics?

Which has better valuation and earnings, NTLA or GYRE?

Does the media refer more to NTLA or GYRE?

Do institutionals & insiders hold more shares of NTLA or GYRE?

Which has more risk & volatility, NTLA or GYRE?

Do analysts recommend NTLA or GYRE?

Is NTLA or GYRE more profitable?

Summary

How does Gyre Therapeutics compare to Trevi Therapeutics?

Is TRVI or GYRE more profitable?

Which has more risk and volatility, TRVI or GYRE?

Do analysts recommend TRVI or GYRE?

Does the media refer more to TRVI or GYRE?

Do insiders and institutionals believe in TRVI or GYRE?

Which has stronger valuation & earnings, TRVI or GYRE?

Summary

How does Gyre Therapeutics compare to Pharvaris?

Which has more risk & volatility, PHVS or GYRE?

Do institutionals and insiders believe in PHVS or GYRE?

Does the media prefer PHVS or GYRE?

Do analysts prefer PHVS or GYRE?

Is PHVS or GYRE more profitable?

Which has better earnings and valuation, PHVS or GYRE?

Summary

How does Gyre Therapeutics compare to Aurinia Pharmaceuticals?

Which has more volatility & risk, AUPH or GYRE?

Do analysts prefer AUPH or GYRE?

Is AUPH or GYRE more profitable?

Which has better earnings and valuation, AUPH or GYRE?

Does the media refer more to AUPH or GYRE?

Do insiders and institutionals believe in AUPH or GYRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GYRE vs. The Competition

Gyre Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools